1.00 / AMA PRA Category 1 CreditTM 1.00 / CE for Nurse Practitioners
Jointly provided by Global Education Group and Physicians' Education Resource®, LLC (PER®)
Supported by an educational grant from Amgen Inc.
This activity will serve as a call to action and will bring together a cardiologist, a specialty NP, a patient advocate, and a managed care representative to address the limited access to PCSK9 inhibitors. This multidisciplinary panel will unite to discuss this issue and raise awareness in hopes of changing policies to allow more widespread access to PCSK9 inhibitors.
The educational design of this activity addresses the needs of lipidologists, cardiologists, and specialty allied health professionals with an interest in the diagnosis and management of hypercholesterolemia.
At the conclusion of this activity, participants should be better able to:
Identify high-risk individuals, including those with residual ASCVD risk such as familial hypercholesterolemia, diabetic dyslipidemia, and/or statin intolerance who would benefit for PCSK9 therapy
Summarize the evidence on the risks and benefits of new and emerging hypercholesterolemia therapies to guide treatment and management decisions for patients with hypercholesterolemia who are not at goal
Develop effective strategies for patient-centered hypercholesterolemia management including patient education, medication risks/benefits, adherence, and lifestyle modifications
Explain how to implement a team-based approach to improve patient access and adherence to PCSK9 inhibitors
Disclosure of Conflicts of Interest Policy
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Harold E. Bays, MD, FTOS, FACE, FNLA Medical Director/President Louisville Metabolic and Atherosclerosis Research Center Louisville, KY
Dr. Bays discloses the following: Grant/Research Support: Amarin, Amgen, Alere, Allergan, Arisaph, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catabasis, Dr. Reddy, Eisai, Elcelyx, Eli Lilly, Esperion, Ferrer/Chiltern, Gemphire, Gilead, GSK, iSpecimen, Janssen, Johnson and Johnson, Kowa, Merck, Necktar, Nichi-Iko, Novartis, NovoNordisk, Pfizer, Regeneron, Sanofi, Selecta, Takeda, and TIMI
Consultant/Advisor: Alnylam, Akcea, Amgen, AstraZeneca, Eisai, Eli Lilly, Esperion, Ionis (ISIS), Janssen, Johnson and Johnson, Kowa, Merck, Novartis, Prosciento, Regeneron, and Sanofi
Speaker: Amarin, Amgen, Eisai, Kowa, Orexigen, Regeneron, and Sanofi
Kevin C. Maki, PhD Chief Scientist Midwest Biomedical Research Center for Metabolic and Cardiovascular Health Glen Ellyn, IL
Dr. Maki discloses the following: Consultant/Speaker: Amgen, AstraZeneca, and Kowa Pharmaceuticals America, Inc. Grant/Research Support: Amgen and Regeneron.
Joyce L. Ross, MSN, CRNP, CLS, FNLA, FPCNA Independent Consult and Educator Immediate Past President, National Lipid Association Past President Preventive Cardiovascular Nurses Association University of Pennsylvania West Chester, PA
Ms. Ross discloses the following: Speaker: Amarin, Amgen, Sanofi, Regeneron, Kaneka America, and KOWA
Catherine Davis Ahmed, MBA Patient Advocate Vice President, Policy and Outreach FH Foundation Pasadena, CA
Ms. Ahmed has no relevant financial relationships with commercial interests to disclose.
Accredited Provider Disclosure
Global Education Group Planning Staff—Lindsay Borvansky; Andrea Funk; and Liddy Knight have no relevant financial relationships with commercial interests to disclose.
Publishing Staff Disclosures
Physicians' Education Resource®, LLC (PER®) Planning Staff—David Heckard; Maryjo Dixon, RPh; Neelam Davis, PharmD; and Kathleen Bowen have no relevant financial relationships with commercial interests to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians’ Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurse Practitioners
Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 1561024
This activity is accredited for 1.00 contact hour which includes 0.00 hour(s) of pharmacology.
Activity ID #2471E
This activity was planned in accordance with AANP CE Standards and Policies.
Disclosure of Unlabeled Use
This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.